Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Asthma/Allergy -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (21)	2/21/2002 9:18:22 AM
From: Bipin Prasad	Respond to of 86

IDPH's Zevalin received FDA marketing approval yesterday, making it the first radio-labeled antibody for the treatment of non-Hodgkins lymphoma (NHL); drug should reach the market in 30-60 days, ahead of street and company expectations; analysts are encouraged by news. USB Piper Jaffray reiterates their Strong Buy rating; sales estimates for Zevalin remain unchanged at $40 mln in 2002 and $112 mln in 2002; firm believes that (with this early approval) their estimates are on the conservative side. UBS Warburg believes peak sales for Zevalin could approach $500 mln annually and rates IDPH a Buy. Salomon Smith Barney upgrades IDPH to BUY from Outperform